Results indicated, further, that the novel cyclopentanyl analog of 3-deazaadenosine, DZNep, bypassed the inhibitory KDM2B/let-7b/EZH2 axis by preventing H3K27 di- and tri-methylation and reducing cell proliferation, suggesting potential usefulness in the treatment of MDS. Here, KDM2B is linked to myelodysplastic syndrome.